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Study objectives: To detect invisible lung cancer and to determine field of laser radiation
during PDT we developed a full-color fluorescence fiberscopic system. We tested the efficacy
of this system in patients with various bronchial malignancies.
System design: A fiber-optic endoscope was attached to a camera box containing a color
ICCD camera which can detect from 400 to 700nm fluorescence in full-color. Light of
average wavelength 405nm was selected and radiated through the light channel of the
fiberscope from a 300W Xenon lamp.
Patients and methods: We examined nine consecutive patients with bronchial malignancy
admitted in our hospital to receive PDT. Sixteen lesions in these nine patients were observed
with white light and excitation light and the results were compared. Histological examinations
were done by taking biopsy specimens and samples for pathological and cytological
examination. After the diagnosis was confirmed, 2.0 mg/kg Photofrin was injected. Forty eight
hours after the administration of Photofrin, observation of the bronchial wall was made using
a full-color endoscopic fluorescence imaging system just before PDT.
Results: Bright red fluorescence from Photofrin was observed in 14/14 bronchial
malignancies: 3 squamous cell carcinoma, 9 squamous cell carcinoma in situ, metastatic
breast cancer and metastatic islet cell tumor. Bright red fluorescence was also detected in 2/2
squamous dysplasia. Green autofluorescence was observed in the normal part of the bronchus.
Conclusions: Results of the present study suggest that the full-color endoscopic
fluorescence imaging system can be used to detect malignant and premalignant lesions as red
fluorescence against green autofluorescence with Photofrin administration, and this system
*Corresponding author. Tel.: + 81-166-68-2442. Fax: + 81-166-68-2449. E-mail: yohsaki@asahikawa-med.ac.jp
187188 Y. OHSAKI et al.
has the potential to detect absence of autofluorescence in cancerous lesions.
Keywords: Cancer; Detection; Endoscope; Fiberscope; Hematoporphyrin derivatives;
Photodynamic diagnosis
Abbreviations: LIFE, light-induced fluorescence endoscopy; PDT, Photodynamic therapy
INTRODUCTION
PDT is a therapeutic modality used against cancers
involving the use of a photosensitizer and the local
application of laser [1,2]. A hematoporphyrin
derivative, Photofrin (dihematoporphyrin ether
and/or ester) (Axcan Pharma, Quebec, Canada) is
used as the photosensitizer in PDT. Hematoporphyrin
derivatives exhibit red fluorescence when light of
wavelengths around 405nm is radiated [3]. It is
reported that Photofrin is retained selectively by
tumor tissue compared with most normal tissues [4]
except the liver, spleen, and kidney [5,6]. The
fluorescence of hematoporphyrin derivatives in vivo
has been reported in cancers of the lung [7], the
bladder [8], and other sites [9]. Therefore, the
difference in concentration of hematoporphyrin
derivatives in malignant tissue versus that in
surrounding normal tissue is the basis of fluorescence
detection and photodynamic diagnosis.
Normal tissue exhibits green fluorescence [10]
from collagen, nicotinamide-adenine dinucleotide
phosphate and flavin-adenine dinucleotide [11,12]
when excitation light is applied. Three different
systems, LIFE lung system [13] (Xillix, Richmond,
Canada), SAFE-1000 [14] (Asahi Optical, Tokyo,
Japan) and D-LightAF system [15] (Storz, Tuttlingen,
Germany), to detect absence of the autofluorescence
in malignant lesions have been introduced. The LIFE
lung system has two black and white CCDs while
SAFE-1000 has one black and white CCD; these
systems show black and green images. The D-Light
AF system has a color CCD; it shows black and green
images in the autofluorescence mode and dark-red and
purple images in the aminolevulinic acid (ALA)
mode. Images from these systems, even in the ALA
mode of the D-Light AF system, were quite different
from full-color fluorescence images.
ALA has been used for photodetection of early-
stage lung carcinoma and malignant glioma 16-18].
ALA exhibits stronger red fluorescence than Photofrin
by application of the excitation light, and the red
fluorescence can be detected by the naked eye.
However, in dark conditions, color information cannot
be detected by unaided vision. Moreover, the
sensitivity is not good enough to detect auto-
fluorescence from the normal tissue. Development
of detection techniques of fluorescence from cancer-
ous tissue and normal tissue in full-color will define
the location or field spread of cancer, thereby
improving the planning of cancer treatment.
Such color fluorescence observation has not been
possible because the sensitivity of previous CCDs and
image intensifiers was not satisfactory. We recently
developed a high-sensitive color intensified CCD
(ICCD) endoscopic system which enables detection of
400-700nm fluorescence in full-color. We believe
that the introduction of this visual technology to
medical practice will enable discovery of unexpected
cancer lesions during PDT, improved definition of the
field for laser radiation, and color spectrum analysis of
the lesion.
We tested the feasibility of this system in patients
with various bronchial malignancies. In this report, we
present results of color fluorescence detection in nine
cases with a variety of bronchial lesions using a high
sensitive color ICCD endoscopic system.FULL-COLOR FLUORESCENCE ENDOSCOPY 189
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FIGURE Block diagram of the high sensitive full-color fluorescence endoscopic system.
MATERIALS AND METHODS
Full-color Endoscopic Fluorescence Imaging
System [19]
A fiber-optic endoscope was attached to a camera box
containing a color ICCD camera (Hamamatsu
Photonics, Hamamatsu, Japan). The camera box was
connected to a RGB control unit with a RGB frame
memory, image average system, scan converter and
camera control unit. Light of averaged wavelength
405 nm was selected and radiated through the light
channel of the fiberscope from a 300W Xenon lamp.
This wavelength excitation light was selectively
attenuated in observations by a filter, which was
designed for this system. White light from a 300W
Xenon lamp was used for white-light observation.
Data from the color ICCD camera was input to the190 Y. OHSAKI et al.
TABLE Results of fluorescence observation using the fluorescence imaging system
Case Sex Age Site Histology Stage Red fluorescenceS"
M 51 L.M. Islet Meta. Bright
2 F 48 R.TI Adeno Meta. Bright
3 M 74 R.B9 SqCC Tis* Bright
4 M 73 L.B6 SqCC Ia Bright
5 M 65 L.B3 SqCC Ia Bright
6 M 56 L.Lo SqCC Ia* Bright
7 M 81 L.U. SqCC Tis* Bright
L.U. Normal Weak
R.U. Normal Weak
8 M 70 L.B4 SqCC Tis Bright
L.BI+2 Dysplasia Bright
R.B3 Dysplasia Bright
9 M 76 R.B1 SqCC Tis Bright
R.B2 SqCC Tis Bright
R.S. SqCC Tis Bright
L.B3 SqCC Tis Bright
L.Us/Ls SqCC Tis Bright
L.Us SqCC Tis Bright
L, left; R, right; M, main bronchus; TI, truncus intermedius; Lo, lower lobe; U, upper lobe; R.S., right seconcarina; Us, upper segment; Ls, lingular segment;
Us/Ls, bifurcation of Us/Ls; Islet, islet cell tumor; Adeno adenocarcinoma; SqCC, squamous cell carcinoma; Meta., metastasis.
Case with second primary.
"
Cases in which red fluorescence was detected.
Olympus TV system, OTV-F3 (Olympus, Tokyo,
Japan). There was a selector to switch between
fluorescence observation and white light observation.
Output devices were a color monitor, a Macintosh
computer and a video recorder (Fig. 1). Any kind of
endoscope with OES attachment can be used because
the system has an Olympus Endoscopy System (OES)
attachment.
Photosensitizer and PDT
Photofrin was obtained from Wyeth-Lederle Japan
(Tokyo, Japan) at a concentration of 2.5 mg/ml in
sterile saline. Photofrin was injected into the vein at a
dose of 2.0mg/kg 48 h prior to PDT. This was an
approved concentration for PDT. After the obser-
vation using the full-color endoscopic fluorescence
imaging system, patients received PDT at the same
lesion. PDT was done by 75-200J/cm2 excimer dye
laser radiation using EDL-PDT1 (Hamamatsu Photo-
nics, Hamamatsu, Japan).
Patients
Nine consecutive patients with bronchial malignancy
admitted our hospital to receive PDT from May 2000
to July 2001 entered this study. Sixteen lesions in
these nine patients were observed with white light and
with excitation light and its results were compared.
Three patients had squamous cell carcinoma of the
bronchus, four had squamous cell carcinoma in situ,
one had pulmonary metastatic islet cell tumor from
the pancreas and one had bronchial metastasis from
breast cancer. One patient with carcinoma in situ had
two different lesions with squamous dysplasia.
Pathological diagnoses of the lesions had been
confirmed before admission. It is reported that biopsy
sites uptake porphyrin derivatives thereafter exhibit
red fluorescence. To avoid this artifact, these patients
underwent photodynamic diagnosis and PDT more
than two weeks after the biopsies. Table I shows
characteristics of the patients.
Endoscopic Observations
Observations of the bronchus were made by a
conventional bronchoscopy using white light in all
cases to confirm pathological diagnosis and locationFULL-COLOR FLUORESCENCE ENDOSCOPY 191
FIGURE 2 Full color fluorescence images of the bronchus. Green autofluorescence was observed from normal bronchial wall (a). Red bright
fluorescence was detected in metastatic breast tumor (b, case 2), in squamous cell carcinoma (c, case 4). In case 6, white-light observation
showed granular change in upper part of the left B6 (d) and red fluorescence was detected in the fluorescence mode (e). (f) shows fluorescence
image in case 7 with carcinoma in situ.
of the tumor before Photofrin administration.
Histological examinations were done by taking biopsy
specimens and samples for pathological and cytolo-
gical examination. After the diagnosis was confirmed,
Photofrin was injected. Forty eight hours after the
administration of Photofrin, observations of the
bronchial wall were made using a full-color
endoscopic fluorescence imaging system just before
PDT.
All major branches of the bronchus were observed
using the full-color endoscopic fluorescence imaging
system. Color fluorescence images were compared to
the white light images in the diagnosed lesions.
Lesions were considered to be present when bright red
fluorescence was detected in the same part of the
bronchus. Shapes were compared between white light
images and fluorescence images. Biopsy was
considered when lesion with red fluorescence other
than the diagnosed lesion was found.
Patients were well informed about the purpose and
method of the fluorescence observation. All patients
agreed to the observations using the new system in
addition to the normal bronchofiberscopic obser-
vation. No extra premedication or anesthesia was
given other than common medication for bronchofi-
berscopy and PDT. Olympus fiber-optic broncho-
scopy, BF-type 40, was used in the fluorescence
observations.
RESULTS
Bright red fluorescence from Photofrin was observed
in 14/14 bronchial malignancies: three squamous cell
carcinoma, nine squamous cell carcinoma in situ, one
metastatic breast cancer and one metastatic islet cell
tumor (Table I). Bright red fluorescence was also
detected in 2/2 squamous dysplasia. Yellow-green192 Y. OHSAKI et al.
FIGURE 3 Left figure shows the weak red fluorescence which was observed in two different parts in case 7. No pathological abnormality
was found (right).
fluorescence was observed in the normal bronchus in
all cases with or without Photofrin injection (Fig. 2a).
Red fluorescence was not detected in bronchial parts
other than the lesion for PDT, although weak red
fluorescence was observed in two different bronchial
portions in case 7.
Figure 2b shows the fluorescence observation in
case 2 with metastatic bronchial tumor from breast
cancer; right trunchus intermedius was nearly
obstructed with this tumor. Bright red fluorescence
was observed in the fluorescence mode. The bronchial
wall seemed to be red due to the reflection of red
Photofrin fluorescence. Figure 2c shows fluorescence
image of bifurcation of the left upper and lower
bronchus in case 4 with squamous cell carcinoma. In
the white-light observation, white thickness of the
membrane was noticed on the bifurcation. The lesion
exhibited red fluorescence from Photofrin. Figure 2d
shows white-light observation in case 6. White thick
lesion with granular change was found in the upper
wall of the left B6. In the fluorescence observation,
bright red fluorescence was detected (Fig. 2e) as well
as yellow-green fluorescence in the lower part. Figure
2f shows the fluorescence image in case 7. Thick
lesion in the left upper lobe bronchus exhibited bright
red fluorescence. In this case two different parts with
weak red fluorescence were observed. No abnormality
was found in the biopsy specimens from these lesions
(Fig. 3). Other than these two normal bronchial parts
FIGURE 4 Fluorescence finding and pathological finding of squamous dysplasia in case 8.FULL-COLOR FLUORESCENCE ENDOSCOPY 193
with weak red Fluorescence in case 8, we did not find
undiscovered cancer lesions in the present study.
Bright redfluorescence was observed in case 8 with
carcinoma in situ in the left B4. This case had two
different lesions with squamous dysplasia. These
lesions also exhibited bright red fluorescence. Figure 4
shows fluorescence observation and pathological
finding of the lesion with squamous dysplasia.
DISCUSSION
Lung cancer is the most common cause of cancer
death in Japan and North America [20]. The overall
five-year survival of patients with lung cancer is
approximately 14%. In patients with early lung
cancer, the five-year survival ranges from 40 to 85%.
Most bronchogenic cancers are smoking related
which tend to develop at multiple sites in the bronchus
[21]. In fact, we observed five cases with multiple
lesions including dysplasia in seven cases with
bronchogenic squamous cell carcinoma in the present
study. Case 9 had six different lesions with squamous
cell carcinoma in situ. Carcinoma in situ is
bronchoscopically visible in less than 30% of cases
and microinvasive tumors are visible in only about
two thirds of cases [22]. Therefore, detection of
invisible cancer has long been a challenge. PDT is an
effective method to treat early bronchial cancer.
Clinical application ofPDT is increasing because it is
the most appropriate for treatment of early lung
cancer for patients with impaired heart and lung
function. Observation of fluorescence from Photofrin
in cases of PDT will help to detect invisible early
cancer and to determine the field for laser radiation.
Detection of invisible cancer using bronchoscopy
has been tried in two different methods; detection of
autofluorescence and detection of fluorescence from
porphyrin derivatives. Lack of green autofluorescence
in caner lesions can be detected using LIFE system
[23] and SAFE-1000 system [24,14]. In the LIFE
system, normal tissue is radiated with a blue laser
beam to exhibit green fluorescence while the area with
malignancy does not exhibit; the cancerous part is
thereby recognized as a negative image of the green
fluorescence. Clinical application of these systems
significantly improved detection rate of invisible
cancer of the bronchus [22,25]. The LIFE system was
found to be 50% or more sensitive than white-light
bronchoscopy in the detection of moderate/severe
dysplasia and carcinoma in situ [26]. In contrast, the
LIFE system did not improve detection of squamous
metaplasia or dysplasia in current or former smokers
[27]. Detection of red fluorescence of porphyrin
derivatives in the cancer lesion has been tried [28].
Lam et al. reported detection of red fluorescence from
Photofrin measuring the red and green ratio in early
lung cancer using a low dose Photofrin injection; they
detected four invisible early lung cancers in four
patients using a ratio fluorometer probe [29]. D-Light
AF system is designed to detect green autofluores-
cence as well as red fluorescence from ALA [15].
Although this system has the potential to detect
fluorescence of other porphyrin derivatives in the
ALA mode, simultaneous detection of different color
fluorescence is not possible.
Our system made possible observation from 400 to
700nm fluorescence in full-color, although the
averaged 405 nm was attenuated because this is the
wavelength of excitation light. The source of
fluorescence in this particular lesion can be deter-
mined by observing color image of the portion; for
example, green fluorescence was observed from the
normal tissue, red fluorescence from cancerous part
and brown fluorescence from bleeding in case 4. In the
present study, 16 out of 16 malignant and premalig-
nant lesions were detected as lesions exhibiting red
fluorescence with Photofrin administration. Differ-
ence in the red fluorescence between squamous cell
carcinoma, carcinoma in situ and dysplasia was not
distinguishable. Red fluorescence was not found in the
bronchus other than in the prediagnosed cancerous or
dysplastic lesions in the present study, except for the
weak reddishness observed in two different parts in
case 7; no malignant changes were found in the biopsy
specimens from these portions. The red fluorescence
in these lesions was easily distinguishable from that of
malignant lesions.
ALA induced protoporphyrin IX exhibits 630nm
fluorescence which is identical to the wavelength of194 Y. OHSAKI et al.
Photofrin fluorescence. The second generation hema-
toporphyrin derivatives are under development and
exhibit fluorescence between 650 and 700nm. Our
system can detect fluorescence at these wavelengths
and can, therefore, be used in the photodynamic
diagnosis using porphyrin derivatives other than
Photofrin and ALA.
Although a larger study population is needed to
assess the advantage of full-color autofluorescence
observation to detect early lung cancer in clinical
practice, absence of autofluorescence in cancerous
lesions was observed even without Photofrin admin-
istration in all cases in the present study. The results of
the present study suggest that the full-color endo-
scopic fluorescence imaging system can be used to
detect malignant and premalignant lesions; as red
fluorescence against green autofluorescence with
Photofrin administration, and this system has the
potential to detect absence of autofluorescence in
cancerous lesion. We believe that detection and
diagnosis of malignant and premalignant lesions by
analyzing color fluorescence images will be possible
in the near future using a flourofiberscopy like ours.
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